CARDIOL THERAPEUTICS INC-A (CRDL) Stock Analyst Earnings Estimates
NASDAQ:CRDL - Nasdaq - CA14161Y2006 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 80K | -100.00% | 19.485M | 125.16M 542.34% | 202.1M 61.47% | 336.27M 66.39% | 370.4M 10.15% | 439.8M 18.74% | |||||||
| EBITDA YoY % growth | -13.98M -99.43% | -20.46M -46.35% | -38.44M -87.88% | -24.48M -6.97% | -23.46M 28.17% | -32.773M -35.10% | -30.806M 22.80% | -29.36M 4.70% | 28.743M 197.90% | 132.33M 360.39% | 187.63M 41.79% | 285.96M 52.41% | 341.78M 19.52% | 388.72M 13.73% | |
| EBIT YoY % growth | -14.13M -99.01% | -20.69M -46.43% | -38.66M -86.85% | -39.79M -6.93% | -29.07M 27.95% | -40.494M -35.22% | -37.842M 6.04% | -34.221M 9.57% | -13.413M 60.80% | 70.331M 624.35% | 143.09M 103.45% | 268.67M 87.76% | 317.57M 18.20% | 382.68M 20.50% | |
| Operating Margin | N/A | N/A | -48,325.00% | N/A | N/A | N/A | N/A | N/A | -68.84% | 56.19% | 70.80% | 79.90% | 85.74% | 87.01% | |
| EPS YoY % growth | N/A | N/A 12.54% | N/A -10.14% | -0.54 8.50% | -0.44 10.20% | -0.55 -15.91% | -0.53 -3.00% | -0.77 -45.63% | -0.19 75.60% | 0.41 319.02% | 0.99 142.49% | 2.32 134.02% | 2.80 20.89% | 3.19 13.82% |
All data in CAD
| Q2 / 25 | Q3 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.12 -22.40% | -0.13 26.33% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -9.384M -21.22% | -10.302M 27.14% |
All data in CAD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.10 28.57% | -0.14 | 0.04 | 29.97% |
| Q4 2024 Q2Q % growth | -0.09 25.00% | -0.13 | 0.04 | 32.64% |
| Q3 2024 Q2Q % growth | -0.18 -100.00% | -0.12 | -0.06 | -47.06% |
| Q2 2024 Q2Q % growth | -0.10 16.67% | -0.13 | 0.03 | 24.59% |
| Q1 2024 Q2Q % growth | -0.14 -27.27% | -0.13 | -0.01 | -5.58% |
| Q4 2023 Q2Q % growth | -0.12 | -0.12 | 0.00 | 1.96% |
| Q3 2023 Q2Q % growth | -0.09 30.77% | -0.12 | 0.03 | 26.47% |
| Q2 2023 Q2Q % growth | -0.12 -20.00% | -0.13 | 0.01 | 5.88% |
| Q1 2023 Q2Q % growth | -0.11 21.43% | -0.15 | 0.04 | 28.10% |
| Q4 2022 Q2Q % growth | -0.12 -9.09% | -0.16 | 0.04 | 24.10% |
| Q3 2022 Q2Q % growth | -0.13 8.96% | -0.15 | 0.02 | 12.10% |
| Q2 2022 Q2Q % growth | -0.10 37.50% | -0.14 | 0.04 | 29.97% |
| Q1 2022 Q2Q % growth | -0.14 46.15% | -0.17 | 0.03 | 19.26% |
| Q4 2021 Q2Q % growth | -0.11 26.67% | -0.15 | 0.04 | 28.10% |
| Q2 2021 Q2Q % growth | -0.16 | -0.14 | -0.02 | -12.04% |
| Q1 2021 Q2Q % growth | -0.26 -136.36% | -0.14 | -0.12 | -82.07% |
| Q4 2020 Q2Q % growth | -0.15 -25.00% | -0.12 | -0.03 | -22.55% |
| Q1 2020 Q2Q % growth | -0.11 | -0.16 | 0.05 | 32.60% |
| Q4 2019 Q2Q % growth | -0.12 | -0.13 | 0.01 | 9.50% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2021 Q2Q % growth | 306K | -306K | -100.00% | |
| Q2 2021 Q2Q % growth | 80K | 204K | -124K | -60.78% |
| Q1 2021 Q2Q % growth | 51K | -51K | -100.00% | |
| Q4 2020 Q2Q % growth | 255K | -255K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 20% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |